What is Creative Medical Technology Holdings PB Ratio?
Creative Medical Technology HoldingsCELZ +1.50%36 PB Ratio is 1.23 as of Jun. 25, 2026, which is 92% above its 10-year median of 0.64. GuruFocus rates CELZ with a GF Score™ of 36/100 and a GF Value™ of $0.32 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,233 Biotechnology companies, Creative Medical Technology Holdings ranks better than 77.7% on this metric.
CELZ's PB Ratio is ranked better than 77.7% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs CELZ: 1.23
During the past 12 months, Creative Medical Technology Holdings's average Book Value Per Share Growth Rate was -47.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -43.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Creative Medical Technology Holdings was -39.20% per year. The lowest was -43.50% per year. And the median was -41.35% per year.
Back to Basics: PB Ratio
Creative Medical Technology Holdings (NAS:CELZ) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Creative Medical Technology Holdings PB Ratio Related Terms
Creative Medical Technology Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creative Medical Technology Holdings PB Ratio Chart
For the Biotechnology subindustry, Creative Medical Technology Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creative Medical Technology Holdings PB Ratio vs Biotechnology Industry
Creative Medical Technology Holdings PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Creative Medical Technology Holdings (CELZ) has a PB Ratio of 1.23 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Creative Medical Technology Holdings and its competitors. This is 92% above median its historical median of 0.64. Over the past decade, Creative Medical Technology Holdings' PB Ratio has ranged from 0.23 to 2.55. According to the industry distribution chart, Creative Medical Technology Holdings ranks #275 out of 1233 companies in the Biotechnology industry, placing it in the top 22.3%.
Is Creative Medical Technology Holdings' PB Ratio too high?
Creative Medical Technology Holdings' current PB Ratio of 1.23 is 92% above median its 10-year median of 0.64. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 2.55. The Biotechnology industry median PB Ratio is 2.80. Creative Medical Technology Holdings' value of 1.23 is 56.1% below this industry median. Based on the distribution chart, Creative Medical Technology Holdings ranks #275 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Creative Medical Technology Holdings has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Creative Medical Technology Holdings' PB Ratio compare to APM and BCLI?
According to the Biotechnology industry distribution chart, Creative Medical Technology Holdings ranks #275 out of 1233 companies for PB Ratio. This places Creative Medical Technology Holdings in the top 22% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. Creative Medical Technology Holdings' value of 1.23 is 56.1% below this benchmark. Historically, Creative Medical Technology Holdings' own PB Ratio has ranged from 0.23 to 2.55 over the past decade. While the company's 10-year median is 0.64 vs. the industry median of 2.80, Creative Medical Technology Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creative Medical Technology Holdings's current PB Ratio of 1.23 is 56.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Creative Medical Technology Holdings and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creative Medical Technology Holdings's current PB Ratio is 1.23, which is 92% above median its own 10-year median of 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Medical Technology Holdings stock overvalued right now?
Based on GuruFocus' analysis, Creative Medical Technology Holdings (CELZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.32, compared to a current price of $2.03 — trading 534.4% above its estimated fair value. The current PB Ratio is 1.23, which is 92% above median its 10-year median of 0.64 and 56.1% below the Biotechnology industry median of 2.80. Creative Medical Technology Holdings' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Creative Medical Technology Holdings (CELZ), the current PB Ratio is 1.23 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creative Medical Technology Holdings (CELZ) Overvalued in 2026?
Based on GuruFocus' analysis, Creative Medical Technology Holdings stock appears to be overvalued.
The current stock price of $2.03 is trading 534.4% above its estimated GF Value™ of $0.32.
GuruFocus considers Creative Medical Technology Holdings to be Significantly Overvalued.
Key valuation signals for CELZ:
PB Ratio: 1.23 (92% above median its 10-year median of 0.64)
GF Value™: $0.32 vs. price of $2.03 (534.4% above fair value)
Industry Position: 56.1% below the Biotechnology median (#275 of 1233)
No single metric tells the full story. See the CELZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creative Medical Technology Holdings Business Description
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
36GF Score
Get the complete analysis for CELZ
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CELZ has been successfully added to your 
